Last reviewed · How we verify
Flamazine
Flamazine is a Small molecule drug developed by Bio-medical Carbon Technology Co., Ltd.. It is currently in Phase 1 development.
Flamazine, also known as silver sulfadiazine, is a topical antibiotic used to prevent infection in partial thickness and full thickness burns. It is a small molecule that works as a bacterial dihydropteroate synthase inhibitor.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Flamazine |
|---|---|
| Sponsor | Bio-medical Carbon Technology Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines (PHASE1, PHASE2)
- Location- and Frequency-Dependent Effects of Thalamic Temporal Interference Stimulation During Sleep (NA)
- Interaural Frequency and Loudness Mismatch in SSD CI Users (NA)
- Mapping the Healthcare Pathway to Multidisciplinary Assessment of 12-25 Year Olds With Somatic Symptom Disorder
- Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns (PHASE2)
- Cochlear Implantation in Children With Asymmetric Hearing Loss or Single-Sided Deafness Clinical Trial (NA)
- Basel Long COVID-19 Cohort Study and Digital Long COVID Substudy
- Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flamazine CI brief — competitive landscape report
- Flamazine updates RSS · CI watch RSS
- Bio-medical Carbon Technology Co., Ltd. portfolio CI
Frequently asked questions about Flamazine
What is Flamazine?
Who makes Flamazine?
What development phase is Flamazine in?
Related
- Manufacturer: Bio-medical Carbon Technology Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing